Eye infection drug IND accepted

Article

The Investigational New Drug (IND) application for NVC-422, a molecule under investigation by NovaBay Pharmaceuticals for the treatment of eye infections, has been cleared by the FDA, triggering a development milestone payment from Alcon to NovaBay of $1 million.

The Investigational New Drug (IND) application for NVC-422, a molecule under investigation by NovaBay Pharmaceuticals for the treatment of eye infections, has been cleared by the FDA, triggering a development milestone payment from the firm's license partner Alcon to NovaBay of $1 million.

NVC-422 - a molecule in the non-antibiotic anti-infective Aganocide class - has been shown in vitro to combat bacteria (including multi-drug-resistant strains), viruses, yeasts and fungi, and has been proven safe for ocular use in previous in vivo testing. NovaBay hopes that NVC-422 will have applications against both bacterial and viral conjunctivitis, to be used topically in the eye as well as within contact lens solution.

NVC-422 is currently also under investigation for non-ocular indications, including skin infections caused by the "superbug" MRSA.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Subscribe Now!
Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Related Content
An image of two medical professionals in medical scrubs standing and talking in a medical facility. Concept image for surgery, consultant and resident ophthalmologists, immediate sequential bilateral cataract surgery, outcomes for ISBCS and eye care. Image credit: ©Rawpixel.com – stock.adobe.com

Resident and consultant ophthalmologists compare immediate sequential bilateral cataract surgery successes

Lynda Charters
June 12th 2025
Article

A new study compared results to determine a more comprehensive understanding of the relationship between the grade of surgeon and ISBCS outcomes

Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD
July 22nd 2024
Podcast
An older man with glasses sits in a wheelchair. Concept image for cabozantinib and corneal perforation, ocular adverse effects, vascular endothelial growth factor VEGF tyrosine kinase inhibitor TKI. Image credit: ©Photographee.eu – stock.adobe.com

Case report examines corneal perforation associated with tyrosine kinase inhibitor

Lynda Charters
June 10th 2025
Article

Cabozantinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, has previously been associated with hepatic and dermatologic adverse effects

The river Neckar, as seen from historic Heidelberg, Germany. ISS International Spectralis Symposium concept image. Image credit: ©Dreadlock – stock.adobe.com

Full list of topics at the upcoming International SPECTRALIS Symposium

Hattie Hayes
June 9th 2025
Article

More than 35 lectures across seven topics, plus a keynote address, will be featured during the meeting

Marc Labetoulle, MD, PhD, and the logo for the European Society of Ophthalmology (SOE) meeting in Lisbon, Portugal, 7 to 9 June, 2025. Concept image for SOE presentation, poster presentation on dry eye research. Includes the email soe.2025@soevision.org

New dry eye disease study compares two preservative-free artificial tear drops

Hattie Hayes;Marc Labetoulle, MD, PhD
June 7th 2025
Article

Research findings from the multicentre clinical study were presented at the European Society of Ophthalmology (SOE) meeting in Lisbon, Portugal

The Belém Tower (Torre de Belém) in Lisbon, Portugal. Concept image for ophthalmology conference, European Society of Ophthalmology SOE Congress 2025 meeting program and schedule. Image credit: ©PhotosbyPatrick – stock.adobe.com

Keynote lectures and YO sessions at the 2025 SOE Congress

Hattie Hayes
June 7th 2025
Article

Special programming for young ophthalmologists will be hosted in the YO lounge

© 2025 MJH Life Sciences

All rights reserved.